Related Experiment Videos
A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive
Philip L Hazell1, John E Stuart
1University of Newcastle, New South Wales, Australia. hazell@mail.newcastle.edu.au
Insights
Clonidine, when added to psychostimulant medication, effectively reduces conduct problems in children with attention-deficit/hyperactivity disorder. This combination therapy is well-tolerated, with transient side effects, supporting its use for managing ADHD-related conduct issues.
Area of Science:
- Pediatric Psychiatry
- Neurodevelopmental Disorders
- Pharmacological Interventions
Background:
- Attention-deficit/hyperactivity disorder (ADHD) often presents with comorbid oppositional defiant disorder or conduct disorder, posing significant treatment challenges.
- Psychostimulant medications are a cornerstone of ADHD treatment but may not fully address disruptive behavioral symptoms.
- Adjunctive therapies are explored to enhance treatment efficacy for complex ADHD presentations.
Purpose of the Study:
- To evaluate the efficacy and safety of adding clonidine to existing psychostimulant therapy.
- To compare clonidine's effects against a placebo in children with ADHD and conduct or oppositional defiant disorder.
- To assess the impact on conduct symptoms and hyperactivity, as well as side effects.
Main Methods:
- A randomized controlled trial involving children aged 6-14 years with ADHD and comorbid conduct/oppositional defiant disorder.
- Participants received either clonidine syrup (0.10-0.20 mg/day) or a placebo for six weeks, alongside their ongoing psychostimulant treatment.
- Primary outcomes included parent-reported Conduct and Hyperactive Index scores from the Conners Behavior Checklist; side effects were systematically monitored.
Main Results:
- Clonidine significantly improved conduct symptoms compared to placebo (p <.01), with a higher response rate on the Conduct scale.
- No significant difference was observed in the Hyperactive Index between the clonidine and placebo groups.
- Clonidine was associated with transient side effects like sedation and dizziness, and a reduction in systolic blood pressure; however, it also reduced psychostimulant-associated adverse effects.
Conclusions:
- The addition of clonidine to psychostimulant therapy is a viable strategy for reducing conduct symptoms in children with ADHD.
- The combination treatment is generally well-tolerated, with manageable and transient side effects.
- Clonidine offers a beneficial adjunctive treatment option for managing complex ADHD presentations involving disruptive behaviors.
Objective:
To compare clonidine with placebo added to ongoing psychostimulant therapy for the treatment of attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder or conduct disorder.
Method:
Children 6 to 14 years of age recruited through 2000 to 2001 were randomized to receive clonidine syrup 0.10 to 0.20 mg/day (n = 38) or placebo (n = 29) for 6 weeks. Primary outcome measures were the Conduct and Hyperactive Index subscales of the parent-report Conners Behavior Checklist. Side effects were monitored using physiological measures and the Barkley Side Effect Rating Scale.
Results:
Evaluable patient analysis showed that significantly more clonidine-treated children than controls were responders on the Conduct scale (21 of 37 versus 6 of 29; chi2(1) = 8.75, p <.01) but not the Hyperactive Index (13 of 37 versus 5 of 29). Compared with placebo, clonidine was associated with a greater reduction in systolic blood pressure measured standing and with transient sedation and dizziness. Clonidine-treated individuals had a greater reduction in a number of unwanted effects associated with psychostimulant treatment compared with placebo.
Conclusions:
The findings support the continued use of clonidine in combination with psychostimulant medication to reduce conduct symptoms associated with attention-deficit/hyperactivity disorder. Treatment is well tolerated and unwanted effects are transient.